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ABSTRACT
Natural compounds often have complex molecular structures and
unknownmolecular targets. These characteristics make them difficult
to analyse using a classical pharmacological approach. Curcumin,
the main curcuminoid of turmeric, is a complex molecule possessing
wide-ranging biological activities, cellular mechanisms and roles
in potential therapeutic treatment, including Alzheimer’s disease
and cancer. Here, we investigate the physiological effects and
molecular targets of curcumin in Dictyostelium discoideum. We show
that curcumin exerts acute effects on cell behaviour, reduces cell
growth and slows multicellular development. We employed a range of
structurally related compounds to show the distinct role of different
structural groups in curcumin’s effects on cell behaviour, growth
and development, highlighting active moieties in cell function, and
showing that these cellular effects are unrelated to the well-known
antioxidant activity of curcumin. Molecular mechanisms underlying
the effect of curcumin and one synthetic analogue (EF24) were
then investigated to identify a curcumin-resistant mutant lacking the
protein phosphatase 2A regulatory subunit (PsrA) and an EF24-
resistant mutant lacking the presenilin 1 orthologue (PsenB). Using in
silico docking analysis, we then showed that curcumin might function
through direct binding to a key regulatory region of PsrA. These
findings reveal novel cellular and molecular mechanisms for the
function of curcumin and related compounds.
KEY WORDS: Dictyostelium discoideum, Curcumin, Presenilin,
PP2A, Cancer, Alzheimer’s disease
INTRODUCTION
Natural products obtained from plants have been used for thousands
of years as medicines (Butler, 2004; Newman and Cragg, 2007;
Gurib-Fakim, 2006). However, the active compound(s) often have
complicated pharmacology, with multiple cellular targets and effects,
making traditional pharmacological approaches insufficient to
understand their biological activity. These factors preclude standard
approaches to investigate mechanism(s) of action.
Curcumin (diferuloylmethane) is a flavonoid derived from
turmeric, and provides a good example of a natural product with
potential therapeutic activity (Aggarwal and Harikumar, 2009;
Ghosh et al., 2015). Currently, ∼120 clinical trials have sought to
demonstrate its efficacy in the treatment of various diseases (Gupta
et al., 2013), yet an analysis published in 2017 reported that only
17 trials have shown positive outcomes (Heger, 2017). To improve
our understanding of this compound, it is crucial to identify
potential therapeutic targets, and to test related compounds that have
improved chemical characteristics (e.g. solubility) (Oliveira et al.,
2015) that can focus research on relevant therapeutic outcomes.
Curcumin has diverse cellular effects, including the modulation of
transcription and growth factors regulating cell growth and cell
death, and as an anti- or pro-oxidant (Goel et al., 2008; Prasad et al.,
2014; Priyadarsini, 2014; Gupta et al., 2012, 2013; Zhou et al.,
2011). Curcumin has also been extensively investigated for the
treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD),
multiple sclerosis (MS), cardiovascular diseases, cancer, allergy,
asthma, rheumatoid arthritis, diabetes and inflammation (Yang
et al., 2017; Lakey-Beitia et al., 2017; Jurenka, 2009; Srinivasan,
1972; Chougala et al., 2012; Zhang et al., 2013; Tang and
Taghibiglou, 2017; McClure et al., 2017).
The main limitations of the therapeutic use of curcumin are its
poor bioavailability and limited understanding of the cellular effects
in relation to its molecular structure (Gupta et al., 2013). Its structure
consists of two aromatic rings containing o-methoxy phenolic
groups, with a seven-carbon linker consisting of an α,β-unsaturated
β-diketone (Priyadarsini, 2014; Ruby et al., 1995; Selvam et al.,
1995). Thus, modification of these groups, and analysis of distinct
cellular effects and targets, could help with understanding the
potential use of curcumin and its derivatives in medicinal roles.
Dictyostelium discoideum has been used as a tractable model
system for the analysis of compounds with potential therapeutic
function. It is a eukaryote, with a unique lifecycle including single-
celled and multicellular stages, and contains a range of orthologues
to disease-linked proteins (Müller-Taubenberger et al., 2013). It has
also been used to investigate the molecular actions of structurally
and pharmacologically diverse compounds from bitter tastants
(Cocorocchio et al., 2015; Robery et al., 2011, 2013), to flavonoids
(Waheed et al., 2014), to drugs used in the treatment of bipolar
disorder (Williams et al., 1999, 2002) and epilepsy (Chang et al.,
2012; Xu et al., 2007; Elphick et al., 2012; Boeckeler et al., 2006).
Several of these studies have been successfully translated to in vitro
and in vivo animal models (Chang et al., 2015, 2016; Chang et al.,
2013, 2014). InD. discoideum, distinct cellular processes, including
growth, acute cell behaviour and development provide valuable
tools for the analysis of compound function. Numerous studies
usingD. discoideum have employed chemical genetic approaches toReceived 4 October 2017; Accepted 28 November 2017
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identify genes controlling the cellular effects of compounds through
screening mutant libraries to identify potential molecular mechanisms
of compounds (Williams et al., 1999, 2002; Waheed et al., 2014;
Robery et al., 2013). Several recent papers have also developed an
approach to monitor the acute effects of compounds by measuring
changes in cell behaviour (Cocorocchio et al., 2015; Robery et al.,
2011). D. discoideum is also widely used as a model to investigate
development, where cells during starvation aggregate and differentiate
to form multicellular fruiting bodies (Marée and Hogeweg, 2001).
Thus, using D. discoideum provides an advantageous system to
analyse the cellular andmolecular effects of complex natural products.
In this study, we employ D. discoideum to investigate the cellular
and molecular targets of curcumin, for which previous studies have
demonstrated sensitivity (Garige and Walters, 2015; Swatson et al.,
2017). We initially corroborated the effects of curcumin on cell
growth and development and further showed an effect on acute cell
behaviour (Garige and Walters, 2015; Swatson et al., 2017). To
differentiate these cellular effects andmechanisms,we then employed
a range of complex natural and synthetic curcumin derivatives to
highlight key functional groups of curcumin and differentiate these
effects from antioxidant activity. A chemical genetic approach was
then used to investigate the molecular targets of curcumin and a
synthetic derivative. From this approach, two proteins were
identified – the protein phosphatase 2A regulatory subunit PsrA
(Lee et al., 2008), associated with cancer onset (Kiely and Kiely,
2015), and the presenilin 1 orthologue PsenB (Ludtmann et al., 2014),
implicated in AD (De Strooper and Annaert, 2010) – which partially
control the effects of these compounds. In silico modelling of
curcumin binding siteswas thenused topredict a binding site onPsrA.
RESULTS
Curcumin shows distinct effects on acute cell behaviour,
growth and development in D. discoideum
To investigate the cellular effects of curcumin onD. discoideum, we
initially assessed acute cell behaviour changes following compound
exposure (Fig. 1). In these experiments, rapid cell movement was
induced through starvation in the presence of pulsatile cyclic AMP
(cAMP), leading to the expression of a discrete set of genes
(Santhanam et al., 2015). Cell behaviour was recorded using time-
lapse microscopy for a period of 15 min including pre- (5 min) and
post- (10 min) curcumin addition and computer-aided cell tracking
was used to analyse changes in membrane protrusions, normalised
to average protrusions pretreatment (Fig. 1B). From this analysis,
acute cell behaviour was unaffected at concentrations ≤2 µM
but showed a concentration-dependent reduction at increasing
concentrations, with a complete block at 3 µM (****P<0.0001;
Fig. 1B). By plotting average cell behaviour following treatment
against curcumin concentration, a nonlinear regression analysis was
used to calculate an IC50 for the effect of curcumin on acute cell
behaviour as 2.3 µM [95% confidence interval (CI) 2.0-2.6 µM]
(Fig. 1C). These data show an acute effect of curcumin on cell
behaviour in D. discoideum, suggesting the presence of rapidly
modified target(s) involved in cellular behaviour.
We then examined the effect of curcumin treatment on D.
discoideum cell growth. In these assays, growth was assessed in the
presence of increasing concentrations of curcumin over 7 days at
concentrations ranging from 0 to 100 µM (Fig. 1D). By plotting the
rate of exponential growth at each concentration, an IC50 value was
calculated by nonlinear regression curve fitting. Curcumin
completely blocked cell growth at 100 µM with an IC50 of 45.7 µM
(95% CI 41.7-50 µM) (Fig. 1E). These data indicate an effect of
curcumin on D. discoideum cell growth, suggesting cellular target(s)
for the flavonoid involved in this process.
Furthermore, the role of curcumin in regulating multicellular
development was also assessed. When D. discoideum are starved,
this causes cells to aggregate and differentiate to ultimately form
multicellular fruiting bodies over 24 h. The resulting fruiting body
consists of a spore head, containing dormant spores held above
the substratum by dead, vacuolated stalk cells (Williams et al.,
2006). In this process, a further subset of proteins, partially distinct
from those of growth and early development, are employed to
enable development. In these experiments, cells were plated onto
nutrient-deficient solid media, in the absence or presence of
curcumin, at a concentration shown above to block growth, and
Fig. 1. Acute cell behaviour, growth and developmental effects of curcumin on D. discoideum. (A) Curcumin, a diferuloylmethane, was used to assess
multiple roles usingD. discoideum as amodel. (B) Time-dependent changes inD. discoideum cell behaviour (membrane protrusion) were recorded over a 15-min
period (±s.e.m.) at increasing concentrations of curcumin. Data are presented normalised to control conditions, showing a significant difference between
control condition (vehicle) and 3 µM (****P<0.0001) using one-way ANOVA. (C) The concentration-dependent response is illustrated as the normalised reduction
of cell behaviour (protrusion formation) against the Log (concentration) of curcumin, enabling calculation of an IC50 with a 95% CI. (D) D. discoideum cells
were grown with increasing concentration of curcumin, causing a complete block at 100 µM, with (E) normalised concentration-dependent response shown
plotted against Log curcumin (mM) concentration, providing an IC50 with 95% CI. (F) Cells were developed on agar over 22 h in control conditions
(vehicle) and in the presence of 100 µM curcumin. Scale bar: 0.25 mm for both side view images. All experiments were carried out in triplicate.
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fruiting body structure was recorded after 24 h. In the absence of
curcumin, a field of fruiting bodies was formed, with individual
fruiting bodies consisting of spore heads elevated by stalks
(Fig. 1F). In the presence of curcumin (100 µM), cells were able
to form a reduced number of aggregates and were unable to develop
into mature fruiting bodies (Fig. 1F). This suggests an effect of
curcumin on D. discoideum late development, regulating cellular
target(s) involved in differentiation.
Identifying active moieties in curcumin responsible for
distinct effects on acute cell behaviour, growth and
development
To improve our understanding of the distinct effects of curcumin in
D. discoideum, we employed a range of compounds structurally
related to curcumin (both natural and synthetic) to identify structural
components of the curcumin molecule that are necessary for distinct
effects (Fig. 2A). Analysis of the curcumin-related compounds on
acute cell behaviour was carried out as described earlier, with cell
behaviour recorded prior to and following the addition of each
compound, with data describing a loss of membrane protrusions
postaddition (Fig. S1). Secondary plots illustrated dose-dependent
effects and provided an IC50 value specific to each compound
(Fig. S2). From this approach (Fig. 2B), modulation of the phenolic
groups through loss of one (demethoxycurcumin; DMC), or both
(bisdemethoxycurcumin; BDMC), methoxy groups caused a step-
wise reduction in potency in controlling acute cell behaviour (3.5-
and 14-fold change, respectively). Similarly, a major metabolite of
curcumin, tetrahydrocucrumin (THC), lacking the α,β-unsaturated
carbonyl moiety on the seven-carbon linker, leading to loss of
the planar structure of the compound, also showed a reduced potency
(5-fold change). In addition, loss of the diketone group through
formation of the pyrazolic ring (Jadhav et al., 2015) eliminated
the effect on acute cell behaviour. Furthermore, FLLL31 (Yuan et al.,
2014), which has two hydrogens on the central carbon replaced by
methyl groups, and two extra methoxy groups, also showed a
reduction in potency (5-fold). Lastly, two structurally distinct
compounds, EF24 and UBS109, were investigated, with both
compounds considered to be curcumin derivatives (Vilekar et al.,
2015; Yamaguchi et al., 2014), where EF24 showed enhanced
activity (1.8-fold), and UBS109 showed reduced activity (11-fold),
in this model. These data suggest that the diketonemoiety is essential
for triggering curcumin-dependent inhibition of cell behaviour, and
that the presence of the methoxy groups and planar nature of the
molecule (lost in THC), and numerous changes to the basic flavonoid
chemical composition in the structurally distinct compounds,
provided opposite cellular effects on acute cell behaviour.
The assessment of curcumin derivatives on D. discoideum cell
growth provided insight into chemical moieties of curcumin
necessary for this effect. Analysis was carried out as described
earlier, with cell growth recorded over 144 h (Fig. S3), and
secondary plots illustrating dose-dependent effects and providing
IC50 values specific to each compound (Fig. S4). For this cellular
effect (Fig. 2C), modulation of the phenolic groups through loss of
one or both methoxy groups (DMC and BDMC), caused a step-wise
increase in potency in controlling growth (2.5- and 14-fold change,
respectively). Loss of the planar nature of the compound (THC) also
increased potency (1.8-fold change), and the addition of two methyl
and methoxy groups in the synthetic analogue FLLL31 increased
potency (1.5-fold). Loss of the diketone group through the formation
of the pyrazole ring (CuPy) eliminated the effect on acute cell
behaviour (and growth). Both structurally distinct compounds, EF24
andUBS109, showed a significant increase (14- and 26-fold change,
respectively) in potency in this model. These data suggest that the
diketone moiety is essential, and that the phenolic groups play key
roles in curcumin activity in regulating cell growth.
Development assays were also carried out to determine which
structural components of curcumin control potency in delaying
multicellular development in D. discoideum. Here, cells were again
plated on non-nutrient agar containing curcumin derivatives at
concentrations that block growth, and allowed to develop over 24 h,
after which fruiting body morphology was recorded (Fig. 2D). In
these studies, loss of one or both methoxy groups (DMC and
BDMC), loss of the planar structure of the compound (THC), or
substitution of the central hydrogens caused delayed and aberrant
fruiting body morphology (FLLL31). By contrast, loss of the
diketone group through the formation of the pyrazole ring (CuPy)
eliminated the developmental effect, and no effect was seen for both
divergent structures (UBS109 and EF24). These data suggest that
the key moiety of curcumin involved in developmental regulation is
the central diketone group.
Analysis of antioxidant activity of curcumin-related
compounds
Because curcumin has been widely proposed to function as an
antioxidant (Sandur et al., 2007; Gordon et al., 2015), reducing free
radicals, we then assessed this activity for curcumin and related
compounds. Here, we employed the ferric-reducing ability of
plasma (FRAP) assay, monitoring rapid (0 min) and extended
(60 min) antioxidant function (Fig. 3). The strong antioxidant,
ascorbic acid was used as a control. Of the curcumin-related
compounds, THC provided the strongest rapid antioxidant activity,
with CuPy also providing an immediate strong effect. Curcumin
demonstrated time-dependent antioxidant activity, increasing over
the experimental period. Loss of one or two methoxy groups
reduced this effect (DMC and BDMC), and the addition of two
methoxy groups plus two methyl groups (FLLL31), and
modification of the β-diketone moiety or major structural change
(EF24 and UBS109), eliminated antioxidant activity (Fig. 3).
Identification of the molecular targets of curcumin and
analogues using a chemical genetic approach
To investigate distinct molecular targets and mechanisms for these
compounds, we employed a mutant screen using curcumin and
related compounds (Table 1). In these experiments, a library of
D. discoideum insertional mutants was grown at a concentration of
each compound giving an 80-90% reduction in growth over 21 days.
Using this approach, a mutant was isolated, showing resistance
to curcumin, with the mutagenic cassette inserted into the open
reading frame of the protein phosphatase 2A regulatory subunit
gene (psrA; DDB_G0280469) (Rodriguez Pino et al., 2015)
(Fig. 4A). In addition, a mutant was isolated showing resistance
to EF24, with the mutagenic cassette inserted immediately
downstream of the start codon of presenilin B (DDB_G0292310)
(Ludtmann et al., 2014) (Fig. 4A). To confirm that the encoded
proteins regulate sensitivity to the compounds, recapitulated
mutants were used to assess the rate of exponential growth for
each mutant in the presence of the screening compound and a range
of related structures over 24 h (Fig. 4B,C; Figs S5 and S6). In the
presence of curcumin, psrA− showed significant resistance
compared to wild-type cells (P<0.001), in addition to resistance to
EF24 and DMC (P<0.05) (Fig. 4B). Similarly, in the presence of
EF24, psenB− showed significant resistance compared to wild-type
cells (P<0.01), in addition to resistance to UBS109 (P<0.01), but
not curcumin or BDMC (Fig. 4C).
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Because curcumin and EF24 showed effects on both growth and
cell behaviour, we also assessed the resistance of psrA− and psenB−
to the cell behaviour effects of compounds. In these assays, both
mutants were not resistant to curcumin and related compounds
(EF24 and DMC) (Fig. S7). These data highlight the distinct
mechanisms underlying the effects of curcumin and related
compounds on growth and acute cell behaviour.
Ligand-protein docking prediction of curcumin with PsrA
Molecular docking analysis was used to propose an interaction site
for curcumin on PsrA. Here, a tertiary structure of the protein was
based upon the mammalian orthologue, PP2A. This tertiary
structure was then used to calculate the most stable binding site of
curcumin and related compounds, showing the lowest energetic
expenditure. This approach identified a common site, on the
interface between the regulatory subunit B and the scaffold subunit
A (based on crystallography studies of the human PP2A enzyme)
(Cho and Xu, 2007) of the protein, which is predicted to
bind to curcumin (deltaG −7.39), EF24 (deltaG −7.23) and DMC
(deltaG −7.54), but is not targeted by CuPy (deltaG −6.62) (Fig. 5),
consistent with the resistance phenotype shown by the psrA−
mutant.
DISCUSSION
Improving our understanding of the potential therapeutic roles of
curcumin (Heger, 2017; Gupta et al., 2013) might facilitate its use in
medicine. To do this, it is critically important to identify potential
therapeutic targets, and to test related compounds that have improved
Fig. 2. Quantification of the acute cell behaviour, growth and developmental effects of curcumin derivatives on D. discoideum. (A) Structure of natural
and artificial derivatives used in a quantitative structural analysis of curcumin effects inD. discoideum. (B) Concentration-dependent responses were determined
for cell behaviour (protrusion formation) and illustrated as the IC50 for each compound with errors shown as 95% CIs (Figs. S1 and S2). (C) Concentration-
dependent responseswere determined for cell growth and illustrated as the IC50 for each compoundwith errors shown as 95%CIs (Figs. 3 and 4). Data fromB and
C are presented as mean±s.e.m. of triplicate experiments. (D) Cells were developed on agar over 22 h in the absence of compounds (vehicle only), or the
presence of curcumin derivatives at concentrations shown to block growth (100 µM FLLL31, 25 µMDMC, 20 µM BDMC, 100 µM THC, 6 µM EF24, 5 µMUBS109
and 100 µM CuPy). All images are representative of triplicate experiments. Scale bar: 0.25 mm for all side view images.
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chemical characteristics (e.g. solubility) (Oliveira et al., 2015) that can
focus research on relevant therapeutic outcomes. The present study
employed a novel system, the social amoeba D. discoideum, which
enables the dissection of discrete acute, growth and developmental
effects of curcumin. Utilising curcumin-related structures identified
key chemical moieties responsible for the effects of curcumin, and
eliminated an antioxidant mechanism for these effects. The study then
identified two novel targets related to disease conditions that might aid
in the investigation of its role in therapeutic function.
In this study, we initially quantified the potency of curcumin
to regulate distinct aspects of acute cell behaviour, growth and
development inD. discoideum. We show that curcumin provides the
strongest inhibitory effect against acute cell behaviour (with an IC50
of 2.3 µM), with reduced potency against cell growth (with an IC50
of 44 µM) and development (>100 µM) (Fig. 1). These effects
support and extend a previous study (Garige and Walters, 2015),
and provide a platform for a comparative study of related chemicals.
From these combined data, it is likely that curcumin has more than
one molecular target in D. discoideum that play distinct cellular
roles.
We then adopted a quantitative structure activity relationship
approach (QSAR), employing a range of natural and artificial
curcumin-related compounds to assess common and distinct cellular
effects dependent upon the specific chemistry of the compound
(Fig. 2). These studies showed that loss of the diketone group
(in CuPy) blocked activity in all three functional roles (acute
cell behaviour, growth and development), and modification by
substitution of central hydrogens (FLLL31) reduced activity (in
acute cell behaviour and growth), highlighting the key role of this
group in curcumin function. For the remaining compounds, in acute
cell behaviour, curcumin and EF24 showed the most potent activity,
with any change in curcumin structure leading to a reduction of
activity. By contrast, effects of curcumin-related compounds on
growth showed that curcumin is the least potent of all compounds
analysed. In development, a common delay was seen for the
structures most related to curcumin, with no effect from the
divergent artificial analogues (EF24 and UBS109). Independent of
the central role of the diketone group, the remaining curcumin-
related structures analysed here identified key regions of the
chemical structure associated with distinct cell effects. In acute cell
behaviour, the most important moieties were represented by the
methoxy groups and the planar structure adjacent to the diketone
groups, where loss of one or two methoxy groups (DMC and
BDMC) strongly and incrementally reduced potency, and loss of the
central double bonds (in THC) also reduced potency. However, the
two synthetic analogues have a variable potency in blocking cell
behaviour. A similar trend is present in growth inhibition, but
reversed, where the same molecular substitutions that reduced
potency in acute cell behaviour enhanced potency in growth.
Interestingly, curcumin and its closely related analogues delayed
development, but this was not evident for the synthetic analogues.
These data support that curcumin has distinct targets related to acute
cell behaviour, growth and development.
Many of the cellular roles for curcumin have been associated with
the scavenging of reactive oxygen species (ROS) as an antioxidant.
Through the mechanism, antioxidants quench free radicals to inhibit
cellular damage (Nimse and Pal, 2015). In this role, specific
Table 1. Genes encoding putative targets for curcumin and related compound
Chemical Gene ID Gene Product Orthologues Identity
Curcumin DDB_G0281669 LMBR1 family protein Q68DH5 27%
DDB_G0280469 Protein phosphatase 2A regulatory subunit psrA Q15172 46%
DDB_G0293904 NADPH-cytochrome-P450 oxidoreductase ENSP00000393527 33%
DDB_G0288103 Type A von Willebrand factor (VWFA) domain-containing protein
BDMC DDB_G0267524 Translocon-associated protein TRAP gamma subunit Q9UNL2 33%
DDB_G0289907 EGF-like domain-containing protein C-type lectin domain-containing protein
DDB_G0291722 UNC93-like protein MFSD11 O43934-1 31%
DDB_G0272684 Dihydropteridine reductase P09417 41%
EF24 DDB_G0276169 AAA ATPase domain-containing protein Q8NBU5-1 39%
DDB_G0292310 Presenilin B P49768-1 32%
DDB_G0279417 LRRK family protein kinase Roco6
UBS109 DDB_G0287861 Glycine cleavage system H-protein P23434 25%
Insertions in 11 genes that were found to convey resistance to curcumin, BDMC, EF24 and UBS109. For each insertion, Dictybase gene ID, product, orthologues
and % identity to human protein have been indicated.
Fig. 3. Antioxidant activity of curcumin and related structures. Reducing
activity was monitored using the FRAP assay. Initial rapid (0 min) and
sustained (60 min) activity was measured, using ascorbic acid as an
antioxidant standard. Data are presented as mean±s.e.m. of triplicate
experiments.
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regions within the curcumin structure (the diketone moiety and two
phenolic groups) can undergo oxidation by electron transfer and
hydrogen abstraction (Priyadarsini, 2014), and the methoxy groups
of curcumin are necessary for antioxidant effects in a range of
models (Yang et al., 2017). To investigate whether the effects of
curcumin and related compounds on D. discoideum were related to
this effect, a time-dependent assay was used to assess antioxidant
activity (Fig. 6). Surprisingly, THC and CuPy provided the largest
rapid-onset activity, with both these compounds and curcumin
providing strong activity over an extended period. The remaining
compounds showed greatly reduced or no significant antioxidant
function, consistent with a crucial role for the diketone and methoxy
groups in antioxidant function, but not supporting this effect in
the modulation of D. discoideum acute cell behaviour, growth or
development roles. Similar outcomes for curcumin and its
derivatives, shown in anti-inflammatory and antiproliferative
Fig. 4. Loss of psrA and psenB genes provides partial growth resistance to curcumin or its derivatives. (A) Through screening a D. discoideum mutant
library, amutant showing resistance to curcuminwas identified showing an insertion into the protein phosphatase 2A regulatory subunit gene (psrA), and amutant
showing resistance to EF24 was identified showing an insertion into the presenilin B gene (psenB) (blue exons and black introns). (B) Analysis of wild-type (Ax3)
and recapitulated psrA− mutant growth rate confirmed that the psrA− mutant was resistant to curcumin, and additionally to EF24 and DMC, but not BDMC
(Fig. S5). (C) Analysis of wild-type (Ax2) and recapitulated psenB− mutant growth rate showed that PsenB was not resistant to curcumin, but showed confirmed
resistance to EF24, in addition to UBS109 (Fig. S6). Data are presented as mean±s.e.m. of triplicate experiments. *P<0.05; **P<0.01; ***P<0.001;
ns, nonsignificant.
Fig. 5. Molecular docking prediction of PsrA and
curcumin analogues. Tertiary protein structures were
generated with Phyre2, with docking prediction performed
by SwissDock to provide the most stable binding site
(deltaG; Gibbs free energy). Using this approach,
curcumin, DMC and EF24 are predicted to bind to the
same site on PsrA that is not shown for CuPy.
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effects of human-derived cancer cell lines also did not relate to their
ability to modulate ROS (Sandur et al., 2007). Thus, in our study, we
have shown that the antioxidant properties of curcumin and its
derivatives are not related to the cellular effects in D. discoideum
observed here, and these effects are therefore likely to occur through
other mechanisms.
Studies in animal models or animal-derived cells provide
an insight into the potential of natural products as therapies in
humans. However, limiting research to these models precludes
a range of experiments that could provide important step changes
in investigating molecular mechanisms. For example, in D.
discoideum, a range of novel targets for therapies and natural
products have been proposed by using a chemical biology approach
(Cocorocchio et al., 2015; Robery et al., 2011, 2013; Waheed et al.,
2014; Williams et al., 1999, 2002; Chang et al., 2012; Xu et al.,
2007; Elphick et al., 2012; Boeckeler et al., 2006). To apply this
approach to curcumin and its derivatives, we identify one gene
product, PsrA, regulating the function of curcumin, and a second
gene product, presenilin B, regulating the function of the synthetic
analogue EF24.
The D. discoideum psrA gene encodes the orthologue of the
mammalian protein phosphatase 2A (PP2A) regulatory subunit B56
(PPP2R5A). In D. discoideum, this protein has been shown to
regulate cell chemotaxis and differentiation by negatively modulating
glycogen synthase kinase 3 (GSK3) protein function (Rodriguez
Pino et al., 2015; Lee et al., 2008). PP2A is a major Ser/Thr
phosphatase expressed ubiquitously in eukaryotic cells. It is a
heterotrimeric enzyme, consisting of a core dimer formed by the
scaffolding subunit (A) and a catalytic subunit (C) (Sangodkar
et al., 2016). The dimer complexes with one of the several
regulatory subunits. In fact, there are >80 different combinations
of the PP2A holoenzyme, which regulates the activity and cellular
localization of PP2A (Magnusdottir et al., 2009). PP2A regulates
a wide variety of cellular processes, including translation,
transcription, inflammation, differentiation and apoptosis (Van
Hoof and Goris, 2003; Codreanu et al., 2006). PP2A plays a pivotal
role in numerous cellular processes, such as cell proliferation, signal
transduction and apoptosis, and its deregulation is associated with
multiple cancers, AD and increased susceptibility to pathogen
infections (Cho and Xu, 2007). It has been shown that in many
cancers, there is an abnormal function of the PP2A scaffold and
regulatory subunits, supporting its role as a tumour suppressor
(Seshacharyulu et al., 2013; Van Hoof and Goris, 2003). In cancer
treatment, data are conflicting; patients with a range of cancers
improve upon restoring PP2A activity (Kiely and Kiely, 2015), but,
conversely, inhibition of PP2A also leads to programmed cell death
in many tumour cells. Interest in curcumin as an anticancer
treatment is due to a large number of in vitro and in vivo studies
reporting growth arrest of different types of cancer, such as brain,
breast, head and neck, liver, pancreas, colon, prostate, ovary and
skin cancers (Anand et al., 2008; Kunnumakkara et al., 2008; Ghosh
et al., 2015; Klinger andMittal, 2016; DiMartino et al., 2017; Panda
et al., 2017; Singh and Aggarwal, 1995; Bharti et al., 2003). In
addition, curcumin has been demonstrated to exert neuroprotective
effects by maintaining the levels of PP2A subunit B, leading to
tau protein dephosphorylation and/or GSK3β inhibition, which
prevents tau hyperphosphorylation (Shah et al., 2015; Sontag and
Sontag, 2014; Di Martino et al., 2016).
In our study, we demonstrate that loss of PsrA markedly reduces
growth sensitivity to curcumin, EF24 and DMC, suggesting that
these compounds might function to regulate cellular activity
through this protein. We further propose a potential direct binding
of these compounds to PsrA through molecular docking analysis,
in which these molecules bind to PsrA but related (inactive)
compounds do not. Interestingly, the region of interaction identified
in this approach is responsible for interaction with the scaffolding
subunit, which might regulate this function. Thus, binding of
curcumin and derivatives to the PP2A core regulatory dimer might
influence the rate or specificity of binding to the scaffolding subunit
and subsequent cellular function. Therefore, this approach has
provided a novel insight into a mechanism of curcumin in regulating
PP2A activity, with potential impact on therapeutic use.
The D. discoideum presenilin B gene encodes one of two
presenilin proteins, as part of the γ-secretase complex (Ludtmann
et al., 2014). Recent results in D. discoideum have shown that
presenilin proteins play a conserved noncatalytic role which is
independent of proteolytic activity (Otto et al., 2016b). This activity
is conserved between human and D. discoideum proteins, because
the expression of human presenilin 1 in D. discoideum restores
γ-secretase complex function (Ludtmann et al., 2014). In addition, it
has been demonstrated that D. discoideum presenilin/γ-secretase
activity is required for both phagocytosis and cell-fate determination.
Thus, presenilin function and γ-secretase activity are ancient
processes that arose prior to metazoan divergence (McMains
et al., 2010). The human presenilin 1 (PS1) protein, as a key
component of the γ-secretase complex, plays a pivotal role in
amyloid precursor protein (APP) cleavage to generate Aβ, where
aggregates of Aβ provide a hallmark of AD pathology. In addition,
PS1 is a substrate for GSK3β, which is also involved in the
pathology of AD (Otto et al., 2016b). Curcumin has been proposed
to decrease Aβ production by inhibiting GSK3β-mediated PS1
activation (Zhang et al., 2010; Di Martino et al., 2016), and
curcumin downregulates presenilin 1 protein in a dose-dependent
manner to regulate γ-secretase function (Yoshida et al., 2011). As a
result, curcumin might have neuroprotective effects by inhibiting
the generation of Aβ and tau fibrils, but the mechanisms of action
remain unknown. In AD, animal models have shown that curcumin
reduces amyloid levels and protein oxidisation, which are involved
in the cognitive decline process (Baum and Ng, 2004). Furthermore,
in patients with AD, macrophages unable to phagocytose Aβ show
restored/enhanced activity following curcumin treatment (Zhang
et al., 2006). Our study identified and validated a mutant lacking the
presenilin B (PS1 homologue) resistant to curcumin-related EF24
and UBS109, and these compounds could provide interesting
analogues for further study in the treatment of AD.
Numerous targets and effects have been proposed for curcumin
that have led to its investigation for the treatment of several diseases.
Targets include transcription and growth factors, cytokines, and
regulators of cell growth and death (Goel et al., 2008). Furthermore,
curcumin interacts with P-glycoprotein, glutathione, protein kinase
C (PKC; PRKC proteins), ATPase, nuclear factor-κB (NFKB1),
epidermal growth factor receptor (EGFR), phosphatidylinositol 3
kinase (PI3K; PIK3CA), AKT proteins, mTOR and many other
cellular targets (Goel et al., 2008; Prasad et al., 2014; Priyadarsini,
2014; Gupta et al., 2012, 2013; Zhou et al., 2011). In addition,
several studies have examined the heptadienedione moiety, which
possesses two thiol-reactive α,β-unsaturated carbonyl groups (Fuchs
et al., 2009; Ou et al., 2013), that might function to covalently
modify cysteine residues of target proteins to regulate cellular
functions. These results have stimulated many studies to investigate
these targets and effects in a wide range of chronic illnesses such as
AD, PD, MS, cardiovascular diseases, cancer, allergy, asthma,
rheumatoid arthritis, diabetes and inflammation (Yang et al., 2017;
Lakey-Beitia et al., 2017; Jurenka, 2009; Srinivasan, 1972;
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Chougala et al., 2012; Zhang et al., 2013; Tang and Taghibiglou,
2017; McClure et al., 2017). It remains to be examined if the targets
identified in this paper function as upstream modulators or
downstream effectors for these curcumin-regulated effects.
In this study, we demonstrated the use of a chemical biology
approach to highlight active moieties of curcumin with cellular
function using the model system D. discoideum. Based upon
identified effects, we further employed a chemical genetic approach
to identify two possible molecular targets for curcumin and its
derivatives, which have been associated with the pathogenesis of
cancer and AD in animal models and patients. The study therefore
proposes curcumin-related compounds with improved chemical
characteristics, which might provide beneficial therapeutic approaches
for treating a range of diseases that have been proposed to be curcumin
responsive. This approach also highlights a useful model to investigate
natural products with multiple cellular effects, and could aid in the
development of new therapeutics related to natural products.
MATERIALS AND METHODS
Chemicals
The following chemicals were obtained from Sigma-Aldrich (Dorset, UK):
curcumin [(E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione;C1386], demethoxycurcumin [(E,E)-1-(4-hydroxy-3-methoxyphenyl)-7-
(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; D7696], bisdemethoxycurcumin
[(1E,6E)-1,7-bis(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; B6938],
EF-24 {(3E,5E)-3,5-bis[(2-fluorophenyl)methylene]-4-piperidinone; E8409},
FLLL31 [(E,E)-1,7-bis(3,4-dimethoxyphenyl)-4,4-dimethyl-1,6-heptadiene-
3,5-dione; F9057], tetrahydrocurcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-
3,5-heptanedione; 50202], adenosine 3′,5′-cyclic monophosphate (3′,5′-cyclic
AMP; A9501, 200 mM stock solution). Curcumin pyrazole {(E)-3,5-bis[β-(4-
hydroxy-3-methoxyphenyl)-ethenyl]-1H-pyrazole; SL-318} was obtained from
Syninnova. Enaminestore supplied UBS109 [3,5-bis(2-pyridinylmethylidene)-
1-methyl-4-piperidone; Z46034963]. All compounds were dissolved in
dimethylsulfoxide (DMSO, vehicle).
D. discoideum growth assay
D. discoideum cells were harvested and diluted in axenic medium to 2×104
cells/ml. Aliquots of cells (500 µl) were transferred to 24-well plates
containing consistent concentrations of solvent (DMSO) in addition to
indicated compounds. Cells were grown in 24-well plates, at 22°C, and cell
density calculated over 7 days. To provide secondary plots, a rate of
exponential growth was calculated (from 72 h to 120 h) at each
concentration, and normalised to control (solvent only) conditions.
D. discoideum random cell movement and cell development
D. discoideum random cell movement assays and developmental
phenotypes assays were carried out as described (Cocorocchio et al.,
2015; Robery et al., 2011). In these experiments, behaviour was monitored
in cells undergoing random cell movement by taking images every 15 s over
a 15-min period, with 5 min recorded prior to, and 10 min after, compound
addition. A minimum of three independent experiments for each drug
concentration were used, with ≥10 cells quantified per experiment.
Protrusions per cell were averaged over the last 5 min of recording, and
normalised to control (solvent only) conditions. In these experiments,
average (untreated) protrusions per cell were ∼5.7 with a maximum of 6.4
and a minimum of 5.4, consistent with previous reports (Cocorocchio et al.,
2015; Otto et al., 2016a).
D. discoideum restriction enzyme-mediated integration screen
To identify mutants in D. discoideum resistant to curcumin and analogues,
two libraries of insertional mutants containing 5000 mutants (psrA−) and
11,000 mutants (psenB−) were used. Cells were incubated with different
concentrations of each compound over 14 days. Mutants growing in the
presence of each compound were identified as previously described (Robery
et al., 2011; Waheed et al., 2014).
Mutant growth inhibition assay
Cells were grown in shaking suspensions and harvested in early exponential
phase (1.5-2.5×106 cells/ml). Cells were then divided into aliquots and
shaken for 24 h in the presence of solvent only or compound, at a
concentration which blocked growth by ∼50% in a final volume of 2 ml
axenic media. Growth (%) was defined for each wild type and derived
mutant (Ax2 and psrA−; or Ax3 and psenB−), with growth normalised to
relevant wild-type cell growth in the absence of compound (solvent only).
Each condition tested was carried out at least in triplicate.
FRAP assay
FRAP solution was prepared by combining 2 ml TPTZ solution (10 mM
2,4,6-tripyridyl-s-triazine in 40 mM HCl), 2 ml FeCl3 (10 mM) and 20 ml
acetate buffer (300 mM, pH 3.6). The assay was carried out by combining
800 µl FRAP solution with 25 µl of the positive control (1 mM ascorbic
acid) or curcumin-related compounds (to give a final concentration of
31.2 µM), and the absorbancewas measured at 595 nm.Measurements were
obtained in triplicate.
Protein-ligand docking
Protein sequences were obtained from dictybase.org. The tertiary structure
of the D. discoideum protein was predicted using Phyre2 (Protein
Homology/Analogy Recognition Engine V 2.0) (Kelley et al., 2015).
Docking analyses were performed using SwissDock to identify the possible
binding sites in PsrA. UFCS Chimera was used to display the results
obtained from SwissDock (Grosdidier et al., 2011). Results are expressed as
deltaG (Gibbs free energy, where a negative value indicates a spontaneous
interaction).
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Supplementary information 
Supplementary Fig. 1. Raw data of D. discoideum acute response to curcumin derivatives. Time-
dependent changes in D. discoideum cell behaviour (membrane protrusion) were recorded over a 15 
minute period for triplicate independent experiments (± SEM) at increasing concentrations of six 
curcumin derivatives to assess their ability to inhibit protrusion formation. The addition of different 
concentration of each compound at 210 seconds caused a reduction in protrusion formation. Data is 
presented as normalised to control (vehicle) conditions. Analysis with Two-tailed t-test showed 
significant changes after the treatment with: DMC 25 µM, FLLL31 25 µM, THC 20 µM,  BDMC 40 µM, 
EF24 2.5 µM and UBS109 35 µM (p < 0.0001 ****). 
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Supplementary Fig. 2. Quantification of the acute effect of curcumin derivatives on D. discoideum. 
Using a range of structurally related compounds, concentration dependent responses were 
determined for D. discoideum cell behaviour (protrusion formation), and illustrated as the 
normalised reduction in response against the Log (concentration) of each compound (shown with 
errors based on the 95% confidence intervals), enabling calculation of an IC50 values and 95% 
confidence intervals for each compound.  
Supplementary Fig. 3. Raw data of D. discoideum chronic response to curcumin derivatives. D. 
discoideum cells were grown with increasing concentration of curcumin derivatives in triplicate 
independent experiments ± SEM. DMC fully blocked growth at 30 µM, FLLL31 and THC at 100 µM, 
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instead BDMC arrested growth at 20 µ, EF24 and UBS109 inhibiteg proliferation at 6 and 5 µM 
respectively.  
Supplementary Fig. 4. Quantification of the chronic effect of curcumin derivatives on D. 
discoideum. Using a range of structurally related compounds, concentration dependent responses 
were determined for D. discoideum cell growth, and illustrated as the normalised reduction in 
growth against the Log (concentration) of each compound (shown with errors based on the 95% 
confidence intervals), enabling calculation of an IC50 values and 95% confidence intervals for each 
compound.  
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Supplementary Fig. 5. Growth inhibition assay - Ax3 and psrA- in presence of curcumin and its 
derivatives. Cells were grown in shaking suspension in presence of different curcumin derivatives. 
Analysis with Two-tailed t-test showed that psrA- mutants are resistant to curcumin as compared to 
AX2 (*** p < 0.001). psrA- mutants were also resistant to EF24 (* p < 0.05), THC (* p < 0.05) and 
DMC (** p < 0.01) in comparison to AX2. psrA- mutants were not resistant to BDMC, UBS109 and 
FLLL31. Data is provided as mean of at least three independent experiments ± SEM. 
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Supplementary Fig. 6. Growth inhibition assay - Ax2 and psenB- in presence of curcumin and its 
derivatives. Cells were grown in shaking suspension in presence of different curcumin derivatives. 
Analysis with Two-tailed t-test showed that psenB- mutants are resistant to EF24 as compared to 
AX2 (*** p < 0.001). Interestingly psenB- mutants were also resistant to UBS109 (** p < 0.01) in 
comparison to AX2. Results showed that the psenB- mutants were not resistant to curcumin, DMC, 
BDMC, THC and FLLL31. Data is provided as mean of at least three independent experiments ± SEM 
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Supplementary Fig. 7. Assessment of the chronic effect of curcumin and its derivatives on D. 
discoideum mutants. psenB and psrA null mutants were exposed to curcumin, DMC and EF24. The 
mean of the normalised protrusion formation was calculated for the first and the last 5 min for each 
cell line. The first set of graphs shows that the psenB- mutant is not resistant to any of the 
compounds. The second set of graphs illustrates that psrA is sensitive to this range of molecules. 
Data is provided as mean of at least three independent experiments ± SEM. 
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